Human immunodeficiency virus type 1 phenotypes in children with advanced disease treated with long-term zalcitabine

Journal of Infectious Diseases

Volumn 177, Issue 3, 1998, Pages 565-570

  Viani, Rolando M ^a   Smith, Irene L ^a   Spector, Stephen A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; RITONAVIR; ZALCITABINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LONG TERM CARE; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYNCYTIUM;

EID: 0031911586     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514238     Document Type: Article

References (14)

1. Koot M, Vos AHV, Keet RPM, et al. HIV-1 biological phenotype in longterm infected individuals evaluated with an MT-2 cocultivation assay AIDS 1992;6:49-54.
2. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
3. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drag resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996;10:975-81.
4. Spencer LT, Ogino MT, Dankner WM, Spector SA. Clinical significance of human immunodeficiency virus type 1 phenotypes in infected children. J Infect Dis 1994;169:491-5.
5. St. Clair MH, Hartigan PM, Andrews JC, et al. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. J Acquir Immune Defic Syndr 1993;6:891-7.
6. Boucher CAB, Lange JMA, Miedema FF, et al. HIV-1 biological pheno-type and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992; 6:1259-64.
7. Zheng NN, McQueen PW, Hurren L, et al. Changes in biologic phenotype of human immunodeficiency viras during treatment of patients with didanosine. J Infect Dis 1996;173:1092-6.
8. Spector SA, Blanchard S, Wara DW, et al. Comparative trial of two dosages of zalcitabine in zidovudine-experienced children with advanced human immunodeficiency viras disease (ACTG 138). Pediatr Infect Dis J 1997;16:623-6.
9. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency viras infection. N Engl J Med 1994;330:657-62.
10. Denny T, Yogef R, Gelman R, et al. Lymphocyte subsets in healthy children during the first five years of life. JAMA 1992;267:1484-8.
11. Hollinger FB, Bremer JW, Myers LE, Gold JWM, McQuay L, the NIH/ NIAID/DAIDS/ACTG Virology Laboratories. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992;30:1787-94.
12. Japour AJ, Fiscus SA, Arduino JM, Mayers DL, Reichelderfer PS, Kuritzkes DR. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol 1994;32:2291-4.
13. Lathey JL, Spector SA. Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages. J Virol 1991;65:6371-5.
14. Japour AJ, Mayers DL, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture assay for the determination of drag susceptibilities of clinical human immunodeficiency viras type 1 isolates. Antimicrob Agents Chemother 1993:37:1095-101.